Filter
779
Text search:
in
vitro
Featured
94
142
Language
Document type
323
220
113
63
22
21
9
4
3
1
Countries / Regions
30
24
23
22
20
16
15
13
11
11
9
9
8
8
7
7
7
7
6
6
6
5
5
5
5
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
228
147
42
22
20
16
Toolboxes
141
107
85
49
42
31
28
26
16
14
13
12
11
6
5
3
3
3
2
2
1
1
Journal of Infectious Diseases and Therapeutics, 2013, 1, 17-24
Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015
This volume introduces Mongolian traditional medicine and details the nature and uses of medicinal plants found in the country.
The book focuses on the medicinal plants used most commonly in Mongol
...
Buruli ulcer (BU) is a bacterial skin infection that is caused by Mycobacterium ulcerans and mainly affects people who reside in the rural areas of Africa and in suburban and beach resort communitie
...
This guideline provides advice in regards to applications for Marketing Authorisations for antimicrobial veterinary medicinal products (VMPs) on the data required and the methodology to be used for performing an assessment of the risk to public heal
...
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive
...
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
TECHNICAL SPECIFICATIONS FOR TEST SELECTION ESSENTIAL IN VITRO DIAGNOSTIC TESTS FOR SARS-COV-2
Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the
...
These guidelines have been developed for scientific purpose with the main aim to guide the regulatory authority for evaluating probiotic products in our country.
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
Technical specifications for selection of essential in vitro diagnostic tests for SARS-COV-2, 14 June 2021
Afr J Tradit Complement Altern Med. (2016) 13(4):123-131
Out of 400 questionnaires distributed to the participants, 389 were returned with data acceptable for analysis. Ages of the participants ranged from 18 to 75 years (Mean=43 + 11.6). Out of the 272 (69.9%) participants who conceded that th ...
Out of 400 questionnaires distributed to the participants, 389 were returned with data acceptable for analysis. Ages of the participants ranged from 18 to 75 years (Mean=43 + 11.6). Out of the 272 (69.9%) participants who conceded that th ...
Value in Health Regional Issues 4 C (2014) 37-40
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
Communication to Healthcare Professionals Mar-2020
This guideline is intended to assist healthcare professionals in the participation of very important process of continuous surveillance of safety and efficacy of the health products which are used
...
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. Th
...
